Background
Melatonin is a ubiquitous natural substance that is widely distributed in nature, being found both in plants and animals [1] [2] [3] . Melatonin is probably one of the first biologically significant compounds that appeared in living organisms. Although in all mammals including humans, melatonin is primarily synthesized in the pineal gland, its synthesis also occurs in other tissues, such as bone marrow, gut, gastrointestinal tract, lymphocytes, and in various parts of the eye in most mammals, i.e. the retina [4] [5] [6] , the ciliary body [7] and the lachrymal gland [8] .
In the eye, melatonin that is locally synthesized or entering from the circulation may contribute to the regulation of retinomotor movements, rod outer segment disc shedding, dopamine synthesis and release, and intraocular pressure (IOP). Moreover, melatonin is an effective antioxidant and free radical scavenger [9] [10] [11] [12] , which protects the photoreceptor outer segment and other ocular tissues from oxidative damage induced by light [13] [14] [15] [16] [17] [18] .
Glaucoma is a complex disease with a number of risk factors and mechanisms that lead to retinal ganglion cell (RGCs) death. Although an increase in IOP definitely plays a causal role in glaucomatous neuropathy, other factors such as a reduced antioxidant defense system activity and an increase in the nitridergic pathway activity have been suggested as possible additional causes for early stage of glaucomatous damage [19] [20] [21] [22] . The current management of glaucoma is mainly directed at the control of IOP; however, a therapy that prevents the death of ganglion cells should be the main goal of treatment.
Uveitis is a common ophthalmic disorder characterized by an acute, recurrent, or persistent ocular inflammation. Uveitis is associated with the disruption of the bloodocular barrier (BOB) as well as protein leakage and leukocyte infiltration into the aqueous humor. Several lines of evidence support the view that uveitis results from Abstract: Several lines of evidence support the view that increased free radical generation and altered nitric oxide (NO) metabolism play a role in the pathogenesis of highly prevalent ocular diseases, such as glaucoma and uveitis. Data are discussed indicating that melatonin, being an efficient antioxidant that displays antinitridergic properties, has a promising role in the treatment of these ocular dysfunctions. Melatonin synthesis occurs in the eye of most species, and melatonin receptors are localized in different ocular structures. In view of the fact that melatonin lacks significant adverse collateral effects even at high doses, the application of melatonin could potentially protect ocular tissues by effectively scavenging free radicals and excessive amounts of NO generated in the glaucomatous or uveitic eye. damage generated by infiltrated leukocytes that release cytokines and other inflammatory chemical mediators [23] , including arachidonic acid (AA) metabolites [24] , reactive oxygen species (ROS) [25] , nitric oxide (NO) [26] , and superoxide anion [27] , among many others. At present, the therapy for uveitis generally based on the use of corticoids is essentially directed toward pain reduction and to avoid lesions of ocular tissues [23, 25, 27, 28] . However, the immunosuppressive effect of corticoids may contribute to the development of systemic disease. Moreover, this strategy carries with it the attendant risk of cortisonic glaucoma induction that usually follows its chronic use [28] . Despite the fact that uveitis and glaucoma are highly prevalent and major causes of blindness, there are currently no optimal treatments for these ocular diseases. In recent years, melatonin has been identified as a neuroprotector in experimental animal models of various neurological and neurodegenerative disorders [29] [30] [31] . In this context, we will consider evidence supporting that melatonin should be regarded as an important ophthalmic therapeutic resource, particularly for the management of glaucoma and uveitis.
Melatonin biosynthesis in the eye
In most mammals, melatonin is synthesized intraocularly through the same pathway that occurs in the pineal gland [32] . Tryptophan taken up from the blood is converted into serotonin, which is subsequently metabolized to N-acetyl serotonin by the enzyme arylalkylamine N-acetyltransferase (AA-NAT). N-acetyl serotonin is then converted into melatonin by the enzyme hydroxyindole-O-methyltransferase (HIOMT). However, because HIOMT is virtually lacking in the human retina, the major end product of this synthetic pathway may be N-acetylserotonin rather than melatonin [33, 34] .
The earliest finding supporting melatoninÕs biosynthetic pathway in the mammalian retina was the description of HIOMT activity [4] and the demonstration that labeled serotonin is converted into melatonin in the rat retina [5] . The presence of HIOMT in the chicken retina at both protein and mRNA level has been confirmed [35, 36] . The gene encoding HIOMT is selectively expressed in retinal photoreceptors. In a recent study, the promoter of HIOMT gene Otx2 was detected both in the chicken retina and pineal gland [37] . These findings are significant in view of the fact that Otx2 protein is present at Ôthe right place and at the right timeÕ to play a role in the onset of HIOMT gene expression in retinal photoreceptors and pineal gland [37] . AA-NAT levels show a circadian rhythm, peaking at night in the chicken and rat retina [38, 39] . The presence of AA-NAT in the human eye has been well documented [40] . In the rhesus monkey, AA-NAT activity in pineal and retina shows more than a four-fold increase at night [41] .
Melatonin biosynthesis in the retina of the golden hamster is regulated by the light/dark cycle [42] . In addition, the finding that isolated Xenopus photoreceptor cells rhythmically secrete melatonin suggests that photoreceptors contain an endogenous circadian clock that regulates melatonin biosynthesis [43] . This hypothesis has been confirmed in the golden hamster and mouse retinas [6, 44] . In fact, several genes identified as components of the core oscillator in the suprachiasmatic nuclei (SCN) have also been localized in the retina. The clock genes cryptochrome 1 and 2 are expressed in chicken inner retinal neurons and in the ganglion cell layer [45, 46] . Furthermore, Period 1 and Period 2 have been identified in the rat retina inner nuclear layer [47] , and in a few ganglion cells of the mouse and human retina [48, 49] . At present, it is not known whether the circadian rhythms in mammalian photoreceptors are driven by inner retinal clocks through synaptic ribbons or by paracrine outputs. Experiments with the rodless mouse have shown that melatonin synthesis is not abolished by the complete loss of photoreceptors but that its circadian expression disappears [6, 50] . This finding suggests that rods are necessary for the rhythmic synthesis of melatonin. However, new evidences indicate that chick RGCs are able to rhythmically synthesize melatonin, even in isolated conditions [51] .
Regulated by the interaction between a circadian clock and the photic information, retinal melatonin levels rise rapidly after the onset of darkness and decrease after light exposure in the golden hamster and rat [42, 52] . The entire sequence of events has been elegantly studied in chicken photoreceptor cells. The depolarization of photoreceptors that occurs during darkness induces AA-NAT activity by a Ca 2+ and 3¢,5¢-cyclic adenosine monophosphate (cAMP)-dependent mechanism [53] . Depolarization of the photoreceptor membrane opens dihydropyridine sensitive voltagegated Ca 2+ channels resulting in sustained increases in intracellular Ca 2+ concentrations in the inner segments of photoreceptors, which in turn stimulate cAMP formation through activation of calmodulin-dependent adenyl cyclase [54] . Increased levels of cAMP induce AA-NAT gene transcription and increase its activity causing an augmented production of melatonin [55, 56] . Stability of AA-NAT is regulated by cAMP, and light, by decreasing cAMP levels in photoreceptor cells, results in rapid degradation of AA-NAT protein by proteasomal proteolysis [57] .
As for the regulation of melatonin biosynthesis by a circadian clock, the gating process involves an E boxmediated transcriptional activation of the adenyl cyclase gene. This regulates melatonin synthesis by regulating the expression of type 1 adenyl cyclase, and the synthesis of cAMP in photoreceptors [58] . cAMP signaling may play a key role in the input and output components of the central circadian axis, the retina, the SCN, and the pineal gland [58] . In addition to cAMP, binding of AA-NAT to 14-3-3 proteins in retinal photoreceptors appears to be important in the response to light and darkness [59] . During darkness, retinal AA-NAT is phosphorylated and forms a complex with 14-3-3 proteins that protects it from dephosphorylation and degradation. Binding of AA-NAT to 14-3-3 proteins is disrupted by light in photoreceptors, which allow AA-NAT degradation. Although the studies cited earlier have been conducted in the chicken, several in vivo and in vitro studies have established that there is a circadian clock system in the mammalian eye independent from the SCN [60] . Besides the retina, it has been reported that both AA-NAT and HIOMT are present in other ocular structures such as rabbit and rat lens [61, 62] .
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occurs in the retina of either the human or the rhesus monkey. The enzyme HIOMT is present in insignificant quantities in those species. Not only is HIOMT protein and activity undetectable but HIOMT mRNA is detectable only by the most highly sensitive methodology [33, 34, 41] . It should be noted, however, that the amount of melatonin synthesis required for a secreting gland is of a much greater magnitude than for a tissue where melatonin acts locally. Thus, if a small amount of synthesis were to occur, that might be sufficient to promote activity at the local level. In addition, all the preceding steps in the synthetic pathway are present in these tissues, so that synthesis of N-acetylserotonin undoubtedly shows a huge increase shortly after dark onset and drops precipitously at light onset in humans as well as rhesus monkeys. Thus, N-acetylserotonin might conceivably substitute for melatonin or have another role such acting as an antioxidant in the primate eye. Finally, in the human and in the rhesus monkey, circulating melatonin is capable of diffusing into the eye and could potentially act on melatonin receptors. That is possible because melatonin is highly lipophilic and readily diffuses into tissues. In that event, in humans and rhesus monkeys, unlike other mammals such as the rat, the rhythm of activation of melatonin receptors in the eye could be totally dependent on the pineal gland.
Melatonin receptors in the eye
Because most of melatonin functions are attributed to its interaction with specific receptors, the study of the distribution of melatonin receptor subtypes in the eye assumes functional significance [16] . Immunocytochemical analysis of ocular tissues obtained from various species, including chickens, rats, and humans, shows that melatonin receptors MT1 and MT2 (formerly Mel 1a and Mel 1b , respectively) are localized in the cornea, choroid, sclera, retina, and retinal blood vessels [63] [64] [65] [66] [67] [68] [69] , as shown in Fig. 1 . In Xenopus eyes, MT1 melatonin receptors have been described in the corneal epithelium, stroma, sclera, and endothelium [70] , suggesting melatoninÕs involvement in the differential regulation of growth and remodeling of the fibrous and cartilaginous scleral layers that affect eye size and refraction. On the other hand, the localization of melatonin receptors in the iris and ciliary processes could indicate that they may be involved in regulating IOP [71] . The presence of melatonin receptor Mel 1c in the nonpigmented epithelium of the chicken [72] suggests that melatonin may affect the rate of aqueous humor secretion by the ciliary epithelium and the circadian rhythm of IOP.
The Mel 1c receptor subtype was first cloned in the chicken [73] and has never been identified in mammals [74] . The three identified melatonin receptors, namely MT1, MT2 and Mel 1c , show different daily rhythms of protein expression in the retinal pigment epithelium (RPE) and choroid, with peak levels of MT1 and MT2 occurring during the night and peak levels of Mel 1c occurring during the day in the chick [69] .
The presence of MT2 in Xenopus apical microvillar cell membrane but not on the basement membrane of the RPE supports the hypothesis that melatonin is involved in photoreceptor outer segment disk shedding and phagocytosis [70, 74] . It was originally reported that in the human retina, MT2 receptors are highly expressed compared to a relatively lower expression of MT1 receptors [75] ; however, a subsequent study reported similar levels of expression for both melatonin receptor types [65] . As shown in Fig. 1 , MT1 receptors have been identified in RGCs and amacrine cells in rat and guinea pig [65, 76] . MT1 receptors are expressed in photoreceptors and other cell types of the human retina [65, 67, 77] . In humans, MT1 immunoreactivity was found in cell bodies along inner border of the inner nuclear layer, and in its outer border almost exclusively in horizontal cells, in cell bodies within the ganglion cell layer and in the inner segments of rod photoreceptors [65] . In addition, about two-thirds of CA1 and CA2 dopaminergic neurons exhibited MT1 immunolabeling. MT1 receptors were also identified in human and macaque AII amacrine cells, which are critical neurons in the rod pathway of the mammalian retina.
The MT2 receptor is expressed in the sclera, lens, RPE and neural retina of Xenopus eye [68] . In elderly humans, MT2 has recently been localized to ganglion and bipolar cells in the inner nuclear layer, to the inner segments of photoreceptors, and to cellular processes in inner and outer plexiform layers [78] . The presence of melatonin receptors in multiple cell types suggests that melatonin could have multiple physiological functions in the retina (Fig. 1) . In human RGCs, MT1 receptors represent nearly 90% of the total number of melatonin receptors [77] . In one study, the MT1 receptor subtype expression in ganglion and amacrine cells from two patients with AlzheimerÕs disease was found to be significantly higher than in controls [66] , suggesting that in this disease an up-regulation mechanism exists that evolves with very low melatonin levels [79] . The MT1 receptor has been identified in the adventitial cells of retinal vessels, suggesting that melatonin could have an indirect action on vascular smooth muscle [66] .
Based on these studies, it is now well established that melatonin receptors are present in the human eye, despite the lack of apparent melatonin synthesis in this structure. The MT1 and MT2 receptors are responsive to N-acetylserotonin albeit with a considerably lower sensitivity, thus N-actylserotonin which changes rapidly in response to light and dark signals might substitute for melatonin. More importantly, circulating melatonin can interact with these receptors.
Ocular functions of melatonin
Systemic administration of melatonin has been found to produce significant changes in anterior and vitreous chamber depth, suggesting that melatonin may play a role in ocular growth and development [69] . Retinal melatonin acts as a neuromodulator that mediates dark adaptive regulation of retinomotor movements [80] . The expression of MT1 receptors in most dopaminergic amacrine cells in human retina implicates melatonin in the modulation of dopaminergic function [67] . Both dopamine and melatonin are key signaling agents in the regulation of retinal rhythmicity. These two substances are mutually inhibitory, acting as signals for day and night, respectively. It was demonstrated that picomolar concentrations of melatonin selectively inhibit the calciumdependent release of dopamine from rabbit retina [81] . Moreover, experimental evidence that supports the model of mutual signaling between melatonin and dopamine has been provided by Doyle et al. [82] , who demonstrated that in C3H +/+ mice, which lack melatonin and show no circadian rhythmicity of dopamine content, the deficiency could be corrected by cyclical administration of melatonin. The action of melatonin on the rod pathway at the level of horizontal and amacrine cells has been proposed as a unique mechanism by which the retina adapts to low light intensities [65] . A correlation between melatonin levels and the electroretinographic (ERG) response has been shown in human studies which suggest that daily melatonin and ERG cycling are associated [83] . On the other hand, melatonin decreases retinal cAMP accumulation [84] and regulates the activity of the retinal glutamate/glutamine cycle activity [85] .
Oxidative and nitrosative stress in the eye and the role of melatonin as an antioxidant and antinitridergic agent An increasing amount of evidence indicates that free radical generation is a major contributing factor to various eye diseases and that melatonin is an important ocular antioxidant [13, 14] . Eye exposure to intense illumination from focal light [86, 87] , the presence of high oxygen tension in the eye [88] , free radicals generated from phagocytosis and lipid peroxidation [89] as well as age-related oxidation [90, 91] contribute to increased oxidative stress. Exposure of rod photoreceptor outer segments to bright light of 485 nm induces oxidation followed by irreversible damage [18] . Oxidative stress has been proposed as a primary cause for retinopathy in preterm infants because it is associated with low levels of reduced glutathione [92] and vitamin E [93] . Additionally, several lines of evidence support that retinal oxidative damage also plays a significant role in other ophthalmic diseases such as diabetic retinopathy [94, 95] , retinal ischemia [96, 97] , glaucoma [21] , and uveitis [98] , among others.
UV-B radiation augments free radical production in corneal epithelial cells resulting in keratitis, whereas melatonin protects corneal epithelial cells from oxidative damage caused by exposure to UV radiation [99] .
The possibility that melatonin could detoxify highly ROS was originally suggested by Ianas et al. [100] . Shortly thereafter, Poeggeler et al. [9] and Reiter et al. [101] using spin trapping and electron resonance spectroscopy demonstrated melatoninÕs capacity to directly scavenge highly reactive hydroxyl radicals. Since then, several reports have shown that melatonin acts as a free radical scavenger and an efficient antioxidant [2, [102] [103] [104] [105] . Not only melatonin, but also several of its metabolites generated during its free radical scavenging action act as antioxidants [106] . The kynurenic pathway of melatonin metabolism includes a series of radical scavengers with the possible sequence:
In the metabolic step from melatonin to AFMK, up to four free radicals can be consumed [106] [107] [108] [109] . Because of this pathway, melatoninÕs efficacy as an antioxidant is greatly increased. Melatonin has been shown to scavenge free radicals generated in mitochondria, reduce electron leakage from the respiratory complexes and improve ATP synthesis [110, 111] . Moreover, melatonin preserves mitochondrial glutathione levels, thereby enhancing the antioxidant potential [112] . In addition, it was demonstrated that melatonin inhibits the nitridergic pathway activity in the golden hamster retina [113] . In this study, melatonin was found to significantly decrease retinal NOS activity and l-arginine uptake, and additionally to inhibit the accumulation of cGMP induced by both l-arginine and an NO donor. The inhibitory effect of melatonin on retinal NOS activity is consistent with the previously described effect of melatonin on this enzyme
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from other neural structures [114] [115] [116] . However, while the effect of melatonin in those tissues was evident up to 1 nm, a much higher sensitivity to the methoxyindole was evident in the hamster retina, because it is effective even at 1 pm, suggesting that the retinal nitridergic pathway is regulated by physiological concentrations of melatonin [113] . In addition to inhibiting NOS activity, melatonin is able to directly scavenge NO, generating at least one stable product, i.e., N-nitrosomelatonin [117] . By scavenging free radicals, increasing the antioxidant defense system activity, and improving the electron transport chain at the mitochondrial level, melatonin is able to protect ocular tissues from both oxidative and nitrosative damage [13, 14] .
Because the retina in humans is unlikely to synthesize melatonin, it is important to consider the possible role of its precursor N-acetylserotonin as an antioxidant. Numerous studies have now established that N-acetylserotonin has major antioxidant effects. Its mechanism of action and range of effects appears to be similar to melatonin and it has also been reported to be more potent than melatonin in several test systems [118] [119] [120] [121] . Moreover, it has recently been shown that N-acetylserotonin decreases glutamate-induced lipid peroxidation in porcine retinal homogenates [122] .
It was recently demonstrated that the low affinity MT3 melatonin receptor binding site is identical with quinone reductase 2 (QR2) [123] , and that melatonin inhibits the activity of this enzyme [124, 125] and there is evidence that, contrary to previous belief [126] , QR2 is an activating enzyme [127, 128] because its deletion from living organisms leads to increased toxicity of quinones [127] . Thus, inhibition of the enzyme could have antioxidant effects. Moreover, N-acetylserotonin interacts with QR2 and in fact has an affinity for this enzyme that is higher than that of melatonin [125, 129, 130] . Therefore, endogenous levels of N-acetylserotonin are even more inhibitory to QR2 in producing an antioxidant action and may well be the endogenous ligand for this enzyme.
Melatonin and uveitis
Uveitis is a common form of intraocular inflammation that is characterized by the disruption of the BOB, an event that provokes protein leakage and leukocyte infiltration into the aqueous humor. Uveitis is a disease that may produce blindness, i.e. among its sequellae are synequiae, cataract, and macular and optic nerve edema, all frequently associated with loss of vision. Current treatments for uveitis have limited effectiveness and a considerable range of side effects. In recent studies, Kukner et al. [131] and Sande et al. [132] investigated the effectiveness of melatonin as a therapeutic strategy in uveitis. In the Kukner study, intravitreal injections of bovine serum albumin were used to induce uveitis in the guinea pig. Melatonin, vitamin E, or aprotinin were intraperitoneally administered 3 days after albumin injection. A significant increase in leptin expression occurs in the retina, choroid, sclera, and episclera; ganglion cells were edematous and inner plexiform layer thickness increased in uveitic eyes. In animals treated with melatonin, vitamin E, or aprotinin, leptin expression was similar to the control group and edema and histopathological changes were reduced.
Sande et al. [132] studied endotoxin-induced uveitis, another established experimental model for uveitis, giving a single intravitreal injection of bacterial lipopolysaccharide (LPS) in the golden hamster. LPS, a component of Gram-negative bacterial outer membranes, enhances the expression of various inflammatory mediators including tumor necrosis factor (TNF)-a, interleukin (IL)-6 [23] , prostaglandin E 2 [24] , and NO [26, 27] . In this study, a pellet of melatonin was implanted subcutaneously 2 hr before the intravitreal injection of LPS. Twenty-four hours and 8 days after injection, the inflammatory response was evaluated in terms of: (i) integrity of BOB, (ii) clinical signs, (iii) histopathological studies, and (iv) retinal function. Melatonin reduced the leakage of proteins and cells in the anterior segment of LPS-injected eyes, decreased clinical signs, and protected the ultrastructure of BOBs. In animals injected with LPS, a remarkable disorganization of rod outer segment membranous disks was observed, whereas no morphological changes in photoreceptor outer segments were observed in animals treated with LPS plus melatonin. Furthermore, melatonin prevented the decrease in the ERG activity induced by LPS. Melatonin significantly abrogated the LPS-induced increase in retinal NOS activity, TNFa, and nuclear factor jB (NFjB) p50 and p65 subunits levels. These results indicate that melatonin prevents clinical, biochemical, histological, ultrastructural, and functional consequences of experimental uveitis, probably through an NFjB-dependent mechanism. Both groups concluded that their findings justified further investigations of melatoninÕs use as a new therapeutic strategy for the treatment of uveitis.
Melatonin and glaucoma
Glaucoma, a chronic disease characterized by visual field loss, cupping of the optic nerve head, and irreversible loss of RGCs, is a leading cause of blindness worldwide. It is estimated that half of those affected may not be aware of their condition because symptoms may not occur during the early stages of the disease. When vision loss appears, considerable and permanent damage has already occurred. Medications and surgery can help slow the progression of some forms of the disease, but there is no cure at present. Increased IOP is considered the major risk factor in glaucoma, but visual field loss may continue despite successful lowering IOP. Although the clinical features of glaucoma are well described, the mechanisms resulting in optic nerve damage and RGC death remain to be elucidated.
Melatonin concentration in aqueous humor parallels its concentration in plasma, peaking during the dark period [133, 134] . Inasmuch as the circadian rhythm of aqueous humor secretion likely contributes to the circadian rhythm of IOP [135] , it has been suggested that melatonin affects aqueous humor secretion [72] . In nocturnal animals, IOP is low during the light period and high in the dark period [134] [135] [136] [137] . In contrast, studies in diurnally active humans reveal that IOP levels peak during daytime [138] . Although it has been demonstrated that the administration of melatonin reduces IOP in humans [139] , to what extent melatonin levels affect circadian IOP rhythm remains to be defined [140, 141] .
The effect on IOP of topical application of the MT3 (QR2) melatonin binding site agonist 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) was evaluated in glaucomatous monkeyÕs eye [142] . It was demonstrated that 5-MCA-NAT substantially reduces IOP in glaucomatous monkeys with reductions in IOP ranging from 10% on day one up to 19% on day 5, the ocular hypotensive effect lasting for at least 18 hr.
In addition to ocular hypertension, several concomitant factors including elevation of glutamate levels, disorganized NO metabolism, and oxidative damage caused by overproduction of ROS may significantly contribute to glaucomatous neurodegeneration (for a review, see [27] ). In particular, NO is believed to play a significant role in experimental glaucoma [22, 143, 144] . Although NO is a ubiquitous signaling molecule that participates in a variety of cellular functions, in concert with ROS, NO can be transformed into a highly potent and effective cytotoxic entity with pathophysiological significance. NO may also signal through the interaction with reduced cysteines of proteins, changing their function [145] , and it modulates the activity of various proteins that contribute to apoptosis [146] . Furthermore, it has been demonstrated that an extracellular proteolytic pathway in the retina contributes to RGCs death via NO-activated metalloproteinase-9 [147] .
Several studies, most of them based on western blotting or immunohistochemical analysis, addressed the issue of NO involvement in human or experimental glaucoma. Increased levels of neuronal NOS (NOS-1) and inducible NOS (NOS-2) were reported in astrocytes of the lamina cribosa and optic nerve head from patients with primary open-angle glaucoma [148] . In rats whose extraocular veins were cauterized to produce chronic ocular hypertension and retinal damage, increased expression of NOS-2 but not NOS-1 was found in optic nerve head astrocytes [149] . Moreover, elevation of hydrostatic pressure in vitro was associated with upregulation of NOS-2 expression in human astrocytes derived from the optic nerve head [148] . Most importantly, inhibition of NOS-2 was found to protect against ganglion cell loss in the rat cautery model of glaucoma [144] . These data support that activation of NOS, especially NOS-2, may play a significant role in glaucomatous optic neuropathy.
In contrast to these results, however, Pang et al. [150] showed that chronically elevated IOP in the rat induced by episcleral injection of hypertonic saline does not increase NOS-2 immunoreactivity in the optic nerve head nor in ganglion cell layer. Moreover, retinal and optic nerve head NOS-2 mRNA levels did not correlate with either IOP level or severity of optic nerve injury, and, additionally, there was no difference between glaucomatous and nonglaucomatous eyes in terms of NOS-2 immunoreactivity in the optic nerve head. Furthermore, aminoguanidine treatment did not affect the development of pressure-induced optic neuropathy in rats [150] . As already mentioned, these studies did not assess changes in the functional capacity of the retinal nitridergic pathway.
More recently, in another experimental model of glaucoma (induced by intracameral injections of hyaluronic acid (HA)) a significant activation of retinal nitridergic pathway was demonstrated [22] . In this study, it was shown that retinal NOS activity significantly increases in hypertensive eyes, although no changes in the levels of NOS isoforms were observed in HA-treated eyes. Different mechanisms might modulate NOS activity, including changes in substrate supply, protein phosphorylation, and subcellular localization, among others. The intracellular events triggered by ocular hypertension that could explain the association between ocular hypertension and NOS activity, as well as the isoform(s) of NOS whose activity is augmented by HA-induced ocular hypertension, remain to be defined. However, because glutamate activity at N-methyl-D-aspartate (NMDA) receptors is one of the most conspicuous promoters of NOS-1 activity, the increase in glutamate synaptic levels previously demonstrated in HA-treated eyes [151] could account for an increase in nNOS activity in this experimental model. Thus, the activation of NOS in hypertensive eyes can be linked to glutamate levels that, in turn, might be elevated to such an extent that they are toxic for ganglion cells. Also in this regard, it has been shown that RGCs in the nNOS-deficient mouse are fairly resistant to NMDA, while damage in the retina of the eNOS-deficient mouse is not distinguishable from that observed in control animals [152] .
In addition to NOS activity, another limiting step in the regulation of NO biosynthesis is the availability of the precursor l-arginine. l-arginine influx and mRNA levels of cationic amino acid transporter type 1 and 2 (CAT-1 and CAT-2) are significantly increased in the retinas from hypertensive eyes [22] . Purified NOS from different sources has been reported to have a low half-saturating l-arginine concentration (EC 50 10 lm). Because high levels of intracellular l-arginine ranging from 0.1 to 1 mm have been measured in many systems [153] , it is expectable that endogenous l-arginine would support maximal activation of NOS.
Several in vivo and in vitro studies, however, indicate that NO production under physiological conditions can be enhanced by extracellular l-arginine, despite saturating intracellular l-arginine concentrations. This has been termed Ôthe arginine paradoxÕ [154] . One possible explanation could be that intracellular l-arginine is sequestered in one or more pools that are poorly, if at all, accessible to NOS, whereas extracellular l-arginine transported into the cells is preferentially delivered to NO biosynthesis [154] . Therefore, it seems likely that to induce the activation of NOS, an influx of l-arginine is essential.
The co-ordination between NOS activity and l-arginine uptake has been demonstrated in several systems such as diabetic rat retina [155] . A similar coordination between NO biosynthesis and intracellular l-arginine availability seems to occur in the retina from hypertensive eyes. Recently, it was demonstrated that activation of NMDA receptors in cultured retinal cells promoted an increase in the intracellular l-arginine pool available for NO synthesis [156] . In this process, the increase in both NOS activity and l-arginine influx could be triggered by higher levels of synaptic glutamate levels in retinas from eyes injected with HA [151] . Notably, it was demonstrated that both diurnal and nocturnal retinal melatonin levels decreased in hypertensive eyes [21] . In addition, a significant decrease in the retinal antioxidant defense system activity was observed in the retinas from eyes injected with HA. Taking into account the conclusive evidence from numerous studies showing that melatonin has significant antioxidant and antinitridergic activity, together with the correlative evidence that retinal melatonin levels are reduced in tandem with the decrease in the antioxidant defense system activity and the increase in the retinal nitridergic pathway, it is tempting to postulate that a causal relationship exists between these phenomena.
Defected mitochondrial respiratory chain, in addition to causing a severe ATP deficiency, often augments ROS generation in mitochondria, which enhances pathological conditions and diseases. In fact, mitochondrial dysfunctionassociated oxidative stress has also been implicated as a risk factor in glaucoma patients [157] . In this sense, it was shown that melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production [158] . Moreover, it was demonstrated that melatonin inhibits mitochondrial NOS isoform [159] .
In the glaucoma model induced by HA injections, the retinal nitridergic pathway activation and the decrease in the antioxidant defense system preceded both functional and histological alterations provoked by ocular hypertension. Therefore, it is possible that oxidative stress and an overactivation of the retinal nitridergic system could contribute to the hypertension-induced retinal damage. In the glaucoma model induced by chronic injections of HA, it has been recently shown that a subcutaneous pellet of melatonin significantly prevents the ERG dysfunction and diminishes the vulnerability of RGCs to the deleterious effects of ocular hypertension [160] .
Besides the effect of melatonin as a retinal antioxidant which could protect RGCs from ocular hypertensive damage, the pathogenic role of oxidative stress in increasing IOP by reducing aqueous outflow facility is supported by various experimental studies performed in vitro and in vivo. In vitro treatment of human trabecular meshwork cells with hydrogen peroxide alters cellular adhesion and integrity [161] . In an animal study, perfusion of trabecular meshwork cells with peroxide has shown to reduce aqueous humor drainage from the anterior chamber of the calfÕs eye [162] . Moreover, human trabecular meshwork endothelium has been reported to be an enriched site of NO synthesis. NO can interact with oxygen or metals, such as copper or iron, to modulate outflow resistance of the trabecular meshwork [163] . In this way, being an effective antioxidant and an antinitridergic melatonin can be beneficial not only at retinal level, but also in the eye anterior chamber, contributing to restore the aqueous humor drainage.
Besides the mechanisms already described, there are other beneficial mechanisms of melatonin for glaucoma treatment (Fig. 2) . Several lines of evidence support that the obstruction of retrograde transport at the optic nerve head results in the deprivation of neurotrophic support to RGCs, leading to apoptotic cell death in glaucoma [164, 165] . An important corollary to this concept is the implication that appropriate enhancement of neurotrophic support will prolong the survival of injured RGC. Of particular importance is the fact that brain-derived neurotrophic factor (BDNF) not only promotes ganglion cell survival following damage to the optic nerve, but also helps to preserve the structural integrity of the surviving neurons, which in turn results in enhanced visual function [166] . As for the link between melatonin and neurotrophins, it has been suggested that melatonin may participate in neurodevelopment and in the regulation of neurotrophic factors [167, 168] . In vitro, melatonin promotes the viability and neuronal differentiation of neural stem cells and increases their production of BDNF [169] . Moreover, ramelteon (a melatonin receptor agonist) is capable of increasing BDNF protein in primary cultures of cerebellar granule cells [170] .
In addition to ocular hypertension, the majority of glaucoma patients show signs of reduced ocular blood flow as well as ischemic signs in the eye, supporting that hemodynamic factors are involved as well in glaucomatous neuropathy. In this sense, it was shown that melatonin could increase the survival rate and rescue and restore injured RGCs in an experimental model of ischemia/ reperfusion in rats [171] , and it counteracts ischemiainduced apoptosis in human retinal pigment epithelial cells [71] .
Finally, while the cellular mechanisms involved in the loss of ganglion cells observed in glaucomatous neuropathy are based on a phenomenon of apoptosis, melatonin was shown to have antiapoptotic properties acting through several mechanisms, such as reduction of caspases, cytochrome c release, and modulation of Bcl-2 and Bax genes, among others. Fig. 2 summarizes some of the ethiopathogenic mechanisms involved in glaucomatous neuropathy and the effect of melatonin on these mechanisms.
Neuroprotective drugs in the treatment of glaucoma
According to Osborne et al. [172] , neuroprotective agents will be more beneficial to patients in which neurons die Fig. 2 . Mechanisms involved in glaucomatous retinal ganglion cell (RGC) apoptosis. Chronic ocular hypertension increases nitric oxide (NO) production, oxidative stress, glutamate synaptic levels, a vascular dysregulation leading to ischemia, as well as a decrease in neurotrophin levels. All these mechanisms can be targeted by melatonin in an opposite way to that induced by glaucoma.
slowly, as seen in glaucoma, than in a disease in which the death of a set of neurons is more rapid. Many compounds such as betaxolol, brimonidine, calcium channel blockers, antioxidants such as vitamin E and coenzyme Q, and Ginkgo biloba extracts have been tried in animals and have been shown to protect the retina against free radical damage and lipid peroxidation [173] . Calcium channel blockers have been shown to neutralize NMDA-induced intracellular Ca 2+ influx. Netland et al. [174] demonstrated a decrease in glaucoma progression in patients treated with Ca 2+ channel blockers. On the other hand, the NMDA antagonist memantine effectively blocked the excitotoxic response of RGCs both in culture and in vivo conditions [175] . However, a recent study showed that the progression of glaucoma was significantly lower in patients receiving a higher dose of memantine than in patients receiving a low dose of memantine, but there was no clear benefit compared to patients receiving placebo.
Melatonin has been demonstrated to be an effective neuroprotective agent in various experimental models and also is being used in the treatment of neurodegenerative diseases such as Alzheimer disease and Parkinsonism, where it has been shown to improve the clinical condition of the patients [29-31, 176, 177] . As discussed earlier, melatonin acts as an efficient retinal antioxidant [17] . In addition, melatonin has been shown to act as a potent inhibitor of the retinal nitridergic pathway because it directly reacts with NO [178] , decreases NOS activity, the uptake of NOS substrate (l-arginine), as well as the increase in cGMP content induced by l-arginine [113] . Moreover, melatonin is a potent inhibitor of NOS-1 and NOS-2 gene expression [179] and it also reduces NOinduced retinal oxidative damage both in vitro [17] and in vivo [180] . In view of this evidence, melatonin could be a promising agent for the management of glaucoma, inasmuch as it exhibits antioxidant and antinitridergic properties, as well as reducing retinal glutamate synaptic levels, among other mechanism (Fig. 2) .
As already mentioned, the current management of glaucoma is mainly directed at the control of IOP. However, it would be clearly preferable for a therapy to have as its main goal the prevention of the death of ganglion cells rather than a symptomatic treatment. The results presented earlier support the conclusion that a decrease in the retinal nitridergic pathway activity as well as an antioxidant treatment may prevent glaucomatous cell death. Melatonin, by itself, may fulfill all these requirements and thus, therapies based on the application of melatonin may have significant potential as a new strategy in glaucoma management.
Concluding remarks
Uveitis and glaucoma are highly prevalent ocular diseases, and constitute main causes of blindness. Thus, they represent a significant public health concern. Uveitis is essentially an inflammatory disease, while glaucoma is an ocular dysfunction highly associated with ocular hypertension and characterized by a loss of RGCs and optic nerve head atrophy. Uveitis and glaucoma differ in several aspects, including causes, risk factors, and retinal cell types involved, among many others. However, several lines of evidence support the inference that uveitis and glaucoma may share some of the ethiopathogenic mechanisms, particularly oxidative damage and increased NO production. Indeed, there is experimental evidence supporting the value of antioxidant and antinitridergic compounds for treating both glaucoma and uveitis [97, 131] . As already mentioned, melatonin by itself exhibits both antioxidant and antinitridergic properties. An effective neuroprotectant for glaucoma treatment must reach the optic nerve head and/or ganglion cells and will therefore probably have to be taken orally, and because it will reach other parts of the body, any side-effect of an appropriate neuroprotectant must be reduced to a minimum [181] . Melatonin, a very safe compound for human use, is highly lipophilic and readily diffuses into tissues. The results presented herein support that alone or combined with an ocular hypotensive therapy (in glaucoma) or with corticosteroid (in uveitis), melatonin should be included in the armamentarium of ophthalmic therapeutic resources, particularly for the treatment of uveitis and glaucoma.
